NOT KNOWN FACTS ABOUT COPYRIGHT 1 MG-SEMAGLUTIDE

The demo reached both equally its Key endpoints, with semaglutide two.four mg demonstrating statistically important and superior advancements in liver fibrosis without any worsening of steatohepatitis, together with resolution of steatohepatitis without any worsening of liver fibrosis in individuals with MASH when compared to placebo.onePancreatiti